🇺🇸 FDA
Patent

US 9849133

Pharmaceutical formulations of xanthine or xanthine derivatives, and their use

granted A61KA61K31/417A61K31/472

Quick answer

US patent 9849133 (Pharmaceutical formulations of xanthine or xanthine derivatives, and their use) held by Eton Pharmaceuticals, Inc. expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Eton Pharmaceuticals, Inc.
Grant date
Tue Dec 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/417, A61K31/472, A61K31/522, A61K31/5575